May 24, 2022
Weil advised Halozyme Therapeutics, Inc., a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies, in its $960 million acquisition of Antares Pharma, Inc., a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The transaction closed on May 24, 2022.
The Weil team that advised Halozyme Therapeutics, Inc. was led by Mergers & Acquisitions partner Michael J. Aiello and included Mergers & Acquisitions partner Sachin Kohli and Mergers & Acquisitions associates Robert Sevalrud, Daniel Sotsky, Ting Liu, Amanda Kadish (Not Yet Admitted in New York) and Daniel Ruzi. The team also included Tax partner Graham Magill; Tax associate Musa Jemal; Executive Compensation & Benefits Head Paul Wessel; Technology & IP Transactions Co-Head Jeffrey Osterman; Technology & IP Transactions/Privacy counsel Olivia Greer; Technology & IP Transactions/Privacy associates Rami Sherman, Dominic Farchione, Jeeyoon Chung, Shannon Coffey and Tamsin Kantor; Global Finance Head Daniel Dokos; Banking & Finance associate Amrita Mukherjee; Real Estate associates Simon Heimowitz and Alexa King (Not Yet Admitted in New York); Regulatory Transactions counsel John O'Loughlin; Regulatory Transactions associate Christina Carone (Admitted in New York Only); Antitrust partner John Scribner; Antitrust counsel Michael Naughton; Antitrust associate Jarui Wang; Patent Litigation and Life Sciences Co-Head Elizabeth Weiswasser; Patent Litigation associates Ian Moore and Rocco Recce (Not Yet Admitted in New York); Employment Litigation Head John P. Barry; Employment Litigation counsel Rebecca Sivitz; Employment Litigation associate Omar Abdel-Hamid (Not Yet Admitted in New York); Securities Litigation counsel Stefania Venezia; and White Collar Defense, Regulatory and Investigations counsel Eileen Citron.